{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:25:01Z","timestamp":1786116301616,"version":"build-2736575974"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T00:00:00Z","timestamp":1783728000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100024017","name":"Sheba Medical Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100024017","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,31]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immune checkpoint inhibitors (ICIs) are increasingly used in oncology, but long-term kidney outcomes in patients with pre-existing CKD (chronic kidney disease) are not well understood. We assessed CKD progression in patients with a baseline eGFR of 15\u201360\u00a0ml\/min\/1.73 m\u00b2 who were treated with ICIs, comparing outcomes with those receiving chemotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective cohort study at Sheba Medical Center between 2015 and 2024. The primary outcome was a composite of new-onset end-stage kidney disease, initiation of kidney replacement therapy, or a\u00a0&amp;gt;30% eGFR decline for at least 90 days. The secondary outcome was time to the first composite event. We used a Cox model with time-varying exposure and a propensity score-matched, new-user active comparator analysis to minimize selection bias.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 3468 patients treated with ICIs, 885 had a baseline of eGFR 15\u201360\u00a0ml\/min\/1.73 m\u00b2; 208 met the inclusion criteria for CKD progression analysis. The composite outcome occurred in 22% of patients, with a shorter time-to-event in CKD stage 4 than in CKD stage 3 (27\u00a0vs. 83 months; P\u00a0=\u00a00.003). Factors associated with CKD progression included hydronephrosis (HR 5.6), smoking (HR 2.09), higher eosinophil counts (HR 4.8), and higher baseline creatinine (HR 3.0). Higher hemoglobin reduced the risk by 12%. ICI exposure was not associated with an increased risk compared with chemotherapy in the time-varying analysis (HR 0.83) or the matched active comparator (HR 0.81). These findings remained consistent in sensitivity analyses excluding patients with genitourinary malignancies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Among patients with eGFR 15\u201360\u00a0ml\/min\/1.73 m\u00b2, systemic anticancer therapy carries a substantial risk of renal decline; however, ICIs do not increase the risk of CKD progression compared to chemotherapy. Outcomes are predominantly driven by baseline renal impairment and individual risk factors, highlighting the necessity of close renal monitoring rather than avoiding ICIs in this vulnerable population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ckj\/sfag224","type":"journal-article","created":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T11:52:42Z","timestamp":1783770762000},"source":"Crossref","is-referenced-by-count":0,"title":["Chronic kidney disease outcomes in patients treated with immune checkpoint inhibitors"],"prefix":"10.1093","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7310-9689","authenticated-orcid":false,"given":"Nabil","family":"Abu-Amer","sequence":"first","affiliation":[{"name":"Institute of Nephrology and Hypertension, Sheba Medical Center , Tel Hashomer ,","place":["Israel"]},{"name":"Gray Faculty of Medical and Health Sciences, Tel Aviv University , Tel Aviv ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Givon","sequence":"additional","affiliation":[{"name":"Gray Faculty of Medical and Health Sciences, Tel Aviv University , Tel Aviv ,","place":["Israel"]},{"name":"Institute of Clinical Pharmacology and Toxicology, Sheba Medical Center , Tel Hashomer ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nirit","family":"Agay","sequence":"additional","affiliation":[{"name":"Biostatistics & Biomathematics Unit, Data & Analytics Division, Sheba Medical Center , Tel Hashomer ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Havi","family":"Murad","sequence":"additional","affiliation":[{"name":"Biostatistics & Biomathematics Unit, Data & Analytics Division, Sheba Medical Center , Tel Hashomer ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noi","family":"Horesh","sequence":"additional","affiliation":[{"name":"Department of Internal medicine C, Sheba Medical Center , Tel Hashomer ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarita","family":"Kunin","sequence":"additional","affiliation":[{"name":"Institute of Nephrology and Hypertension, Sheba Medical Center , Tel Hashomer ,","place":["Israel"]},{"name":"Gray Faculty of Medical and Health Sciences, Tel Aviv University , Tel Aviv ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orit","family":"Erman","sequence":"additional","affiliation":[{"name":"Institute of Nephrology and Hypertension, Sheba Medical Center , Tel Hashomer ,","place":["Israel"]},{"name":"Gray Faculty of Medical and Health Sciences, Tel Aviv University , Tel Aviv ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adva","family":"Vaisman","sequence":"additional","affiliation":[{"name":"Institute of Nephrology and Hypertension, Sheba Medical Center , Tel Hashomer ,","place":["Israel"]},{"name":"Gray Faculty of Medical and Health Sciences, Tel Aviv University , Tel Aviv ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haim","family":"Mayan","sequence":"additional","affiliation":[{"name":"Gray Faculty of Medical and Health Sciences, Tel Aviv University , Tel Aviv ,","place":["Israel"]},{"name":"Institute of Clinical Pharmacology and Toxicology, Sheba Medical Center , Tel Hashomer ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pazit","family":"Beckerman","sequence":"additional","affiliation":[{"name":"Institute of Nephrology and Hypertension, Sheba Medical Center , Tel Hashomer ,","place":["Israel"]},{"name":"Gray Faculty of Medical and Health Sciences, Tel Aviv University , Tel Aviv ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronen","family":"Loebstein","sequence":"additional","affiliation":[{"name":"Gray Faculty of Medical and Health Sciences, Tel Aviv University , Tel Aviv ,","place":["Israel"]},{"name":"Institute of Clinical Pharmacology and Toxicology, Sheba Medical Center , Tel Hashomer ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,11]]},"reference":[{"key":"2026080605064140400_bib1","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"KEYNOTE-189 Investigators: pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"key":"2026080605064140400_bib2","doi-asserted-by":"publisher","first-page":"e200423","DOI":"10.1001\/jamanetworkopen.2020.0423","article-title":"Estimation of the percentage of US patients with cancer who are eligible for immune checkpoint inhibitor drugs","volume":"3","author":"Haslam","year":"2020","journal-title":"JAMA Netw Open"},{"key":"2026080605064140400_bib3","doi-asserted-by":"publisher","first-page":"3801","DOI":"10.1038\/s41467-020-17670-y","article-title":"A decade of immune-checkpoint inhibitors in cancer therapy","volume":"11","author":"Robert","year":"2020","journal-title":"Nat Commun"},{"key":"2026080605064140400_bib4","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1038\/s41581-022-00630-8","article-title":"Diagnosis and management of immune checkpoint inhibitor-associated acute kidney injury","volume":"18:","author":"Sprangers","year":"2022;","journal-title":"Nat Rev Nephrol"},{"key":"2026080605064140400_bib5","doi-asserted-by":"publisher","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann Oncol"},{"key":"2026080605064140400_bib6","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"2026080605064140400_bib7","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"2026080605064140400_bib8","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.ejca.2020.04.025","article-title":"Late immune-related adverse events in long-term responders to PD-1\/PD-L1 checkpoint inhibitors: a multicentre study","volume":"134","author":"Nigro","year":"2020","journal-title":"Eur J Cancer"},{"key":"2026080605064140400_bib9","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1159\/000455014","article-title":"On behalf of Cancer and Kidney International Network Workgroup on immune checkpoint inhibitors. Adverse renal effects of immune checkpoint inhibitors: a narrative review","volume":"45","author":"Wanchoo","year":"2017","journal-title":"Am J Nephrol"},{"key":"2026080605064140400_bib10","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1016\/j.ekir.2020.07.011","article-title":"Incidence and clinical features of immune-related acute kidney injury in patients receiving programmed cell death ligand-1 inhibitors","volume":"5","author":"Seethapathy","year":"2020","journal-title":"Kidney Int Rep"},{"key":"2026080605064140400_bib11","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1093\/ndt\/gfab034","article-title":"Acute kidney injury as a risk factor for mortality in oncological patients receiving checkpoint inhibitors","volume":"37","author":"Garc\u00eda-Carro","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"2026080605064140400_bib12","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1681\/ASN.2019070676","article-title":"Clinical features and outcomes of immune checkpoint inhibitor-associated AKI: a multicenter study","volume":"31","author":"Cortazar","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"2026080605064140400_bib13","doi-asserted-by":"publisher","first-page":"e379","DOI":"10.1093\/oncolo\/oyad001","article-title":"Safety of immune checkpoint inhibitors in patients with advanced chronic kidney disease: a retrospective cohort study","volume":"28","author":"Tiu","year":"2023","journal-title":"Oncologist"},{"key":"2026080605064140400_bib14","doi-asserted-by":"publisher","first-page":"103169","DOI":"10.1016\/j.critrevonc.2020.103169","article-title":"Exploring the knowledge gap of immune checkpoint inhibitors in chronic renal failure: a systematic review of the literature","volume":"157","author":"Mroue","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"key":"2026080605064140400_bib15","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1053\/j.ajkd.2019.05.031","article-title":"Timing of recovery from moderate to severe AKI and the risk for future loss of kidney function","volume":"75","author":"Siew","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"2026080605064140400_bib16","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1038\/kisup.2013.79","article-title":"Risk factors for chronic kidney disease: an update","volume":"3","author":"Kazancio\u011flu","year":"2013","journal-title":"Kidney Int Suppl (2011)"},{"key":"2026080605064140400_bib17","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s40266-020-00747-0","article-title":"Adverse drug events in patients with chronic kidney disease associated with multiple drug interactions and polypharmacy","volume":"37","author":"Sommer","year":"2020","journal-title":"Drugs Aging"},{"key":"2026080605064140400_bib18","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","article-title":"2021 clinical practice guideline for the management of glomerular diseases","volume":"100","author":"KDIGO","year":"2021","journal-title":"Kidney Int"},{"key":"2026080605064140400_bib19","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1093\/aje\/kwm324","article-title":"Immortal time bias in pharmacoepidemiology","volume":"167","author":"Suissa","year":"2008","journal-title":"Am J Epidemiol"},{"key":"2026080605064140400_bib20","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1136\/bmj.b5087","article-title":"Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes","author":"L\u00e9vesque","year":"2010","journal-title":"Br Med J"},{"key":"2026080605064140400_bib21","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1002\/sim.8502","article-title":"Variance estimation when using propensity-score matching with replacement with survival or time-to-event outcomes","volume":"39","author":"Austin","year":"2020","journal-title":"Stat Med"},{"key":"2026080605064140400_bib22","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/978-94-015-7983-4","article-title":"Cox-type regression analysis for large numbers of small groups of correlated failure time observations","volume-title":"Survival Analysis: State of the Art","author":"Lee","year":"1992"},{"key":"2026080605064140400_bib23","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1053\/j.ajkd.2021.05.012","article-title":"Incidence and predictors of CKD and estimated GFR decline in patients receiving immune checkpoint inhibitors","volume":"79","author":"Chute","year":"2022","journal-title":"Am J Kidney Dis"},{"key":"2026080605064140400_bib24","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1007\/s00262-025-04147-4","volume":"74","author":"Cheng","year":"2025","journal-title":"Cancer Immunol Immunother"},{"key":"2026080605064140400_bib25","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1093\/ndt\/gfad271","article-title":"Risk factor analysis for a rapid progression of chronic kidney disease","volume":"39","author":"Anne H S Vestergaard","year":"2024","journal-title":"NDT"},{"key":"2026080605064140400_bib26","doi-asserted-by":"publisher","first-page":"e003467","DOI":"10.1136\/jitc-2021-003467","article-title":"Acute kidney injury in patients treated with immune checkpoint inhibitors","volume":"9","author":"Gupta","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2026080605064140400_bib27","doi-asserted-by":"publisher","DOI":"10.1177\/17588359221111703","article-title":"Association of proton pump inhibitor use with survival outcomes in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis","author":"Chen","year":"2022","journal-title":"Ther Adv Med Oncol"},{"key":"2026080605064140400_bib28","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1159\/000538274","article-title":"Association of proton pump inhibitor use and immune checkpoint inhibitor-mediated acute kidney injury: a meta-analysis and a review of related outcomes","volume":"55","author":"Mohan","year":"2024","journal-title":"Am J Nephrol"},{"key":"2026080605064140400_bib29","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.2215\/CJN.00990119","article-title":"The incidence, causes, and risk factors of acute kidney injury in patients receiving immune checkpoint inhibitors","volume":"14","author":"Seethapathy","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026080605064140400_bib30","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1016\/j.kint.2024.09.017","article-title":"Diagnosis and management of immune checkpoint inhibitor\u2013associated nephrotoxicity: a position statement from the American Society of Onco-nephrology","volume":"107","author":"Herrmann","year":"2025","journal-title":"Kidney Int"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ckj\/advance-article-pdf\/doi\/10.1093\/ckj\/sfag224\/68759335\/sfag224.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/19\/8\/sfag224\/68759335\/sfag224.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/19\/8\/sfag224\/68759335\/sfag224.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T09:06:48Z","timestamp":1786007208000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/doi\/10.1093\/ckj\/sfag224\/8732560"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,11]]},"references-count":30,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,7,31]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfag224","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,7,11]]},"article-number":"sfag224"}}